Abstract
The exact changes in cytokine production and clinical implications of the increased cytokine levels following operative trauma remain unclear. In this study, systemic production of a spectrum of cytokines, including IL1α, IL1β, IL6, IL8, IL10, and IFNγ, was examined in patients undergoing minor elective operative trauma. The levels of IL1 receptor antagonist (ra) and IL6 soluble receptor (sR) were also determined. Although there were no changes in IL1α and IL1β plasma levels during the entire observation period, there was a significant rise in IL1 ra level in all patients between postoperative day 1 and postoperative day 14. A significant increase in the IL6 plasma level was seen on days 1, 3, and 7 after surgery and an increase in the IL6 sR level was observed on postoperative days 10 and 14. Interestingly, the IL8 plasma values had risen significantly on days 1 and 3 following the operation. In some patients, an elevation in IL10 plasma level was noted on days 1 and 3 postsurgery. Results demonstrated that even a minor surgical procedure such as cholecystectomy with uneventful wound healing was followed by an appearance in the blood circulation of significant levels of cytokines between day 1 and day 14 after surgery. These observations point to the necessity of searching for methods of down-regulating the systemic cytokine effects after surgical trauma for the routine postoperative management.
Similar content being viewed by others
References
Simone C, Pugnaloni L, Cilli A, Forastieri EMA, Bernardini B, Delogu G, Sorice F: Pharmacokinetic assessment of immunosuppressive activity of antibiotics in human plasma by modification of the mixed lymphoreaction. Crit Care Med 12:483–485, 1984
Salo M: Effects of anaesthesia and surgery on the immune response. Acta Anaesthesiol Scand 36:201–220, 1992
Calvano S: Hormonal mediation of immune dysfunction following thermal and traumatic injury.In Advances in Host Defence Mechanism, JM Davies, GT Shires (eds). New York, Raven Press, 1986, pp 111–142
Miller CL, Baker CC: Changes in lymphocyte activity after thermal injury. The role of suppressor cells. J Clin Invest 63:202–210, 1979
Munster AM: Post-traumatic immunosuppression is due to activation of suppressor T cells. Lancet 1:1329–1330, 1976
Wang BS, Heacock EH, Wu AVO, Mannick JA: Generation of suppressor cells in mice after surgical trauma. J Clin Invest 66:200–209, 1980
Winchurch RA, Munster AM: Post-traumatic activation of suppressor cells. J Reticuloendothel Soc 27:83–88, 1980
Constantin MB, Menzoian JO, Nimberg RB, Schmid K, Mannick JA: Association of a circulating immunosuppressive polypeptide with operative and accidental trauma. Ann Surg 185:73–79, 1977
Movat HZ: Tumor necrosis factor and interleukin-1: Role in acute inflammation and microvascular injury. J Lab Clin Med 110:668–681, 1987
Nishimoto N, Yoshizaki K, Tagoh H, Monden M, Kishimoto S, Hirano T, Kishimoto T. Elevation of serum interleukin 6 prior to acute phase proteins on the inflammation by surgical operation. Clin Immunol Immunopathol 50:399–401, 1989
Green DR, Faist E: Trauma and immune response. Immunol Today 9:253–255, 1988
Akira S, Kishimoto T: IL6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev 127:25–50, 1992
Heinrich PC, Castell JV, Andus T: Interleukin 6 and the acute phase response. Biochem J 265:621–636, 1990
Kelso A: Cytokines: Structure, function and synthesis. Current Opin Immunol 2:215–225, 1989
Arai K, Lee F, Miyajima A, Miyatake S, Arai N, Yokota T. Cytokines: Coordinators of immune and inflammatory responses. Annu Rev Biochem 59:783–836, 1990
Marx JL: Cytokines are two-edged swords in disease. Science 239:257–258, 1988
Arend WP, Malyak M, Bigler CF, Smith MF, Janson RW: The biological role of naturally-occurring cytokine inhibitors. Br J Rheumatol 30:49–52, 1991
Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL, Armes LG, Sommer A, Eisenberg SP, Thompson RC: Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343:336–340, 1990
McIntyre KW, Stepan GJ, Kokinsky KD, Benjamin WR, Plocinksy JM, Kaffka KL, Campen RA, Chizzonite RA, Killian PL: Inhibition of interleukin 1 (IL1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL1 receptor antagonist and anti-IL1 receptor monoclonal antibody. J Exp Med 173:931–939, 1991
Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC: Interleukin 1-receptor antagonist reduces mortality from endotoxin shock. Nature 348:550–552, 1990
Alexander HR, Doherty GM, Buresh CM, Venzon DJ, Norton JA: A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med 173:1029–1032, 1991
Everaerdt B, Brouckaert P, Fiers W: Recombinant IL-1 receptor antagonist protects against TNF-induced lethality in mice. J Immunol 152:5041–5049, 1994
Arend WP: Interleukin-1 receptor antagonist: A new member of the interleukin 1 family. J Clin Invest 88:1546–1451, 1991
Dinarello CA, Thompson RC: Blocking IL-1: Interleukin-1 receptor antagonist in vivo and in vitro. Immunol Today 12:404–410, 1991
Zamir O, O'Brien W, Thompson R, Bloedow DC, Fischer JE, Hasselgren PO: Int Reduced muscle protein breakdown in septic rats following treatment with interleukin-1 receptor antagonist. J Biochem 26:943–950, 1994
Moldawer LL: Interleukin 1, TNF alpha and their naturally occurring antagonists in sepsis. Blood Purif 11:128–133, 1993
Tilg H, Trehu E, Atkins MB, Dinarello ChA, Mier JW: Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83:113–118, 1994
Rogy MA, Coyle SM, Olendburg HS, Rock CS, Barie PS, Van-Zee KJ, Smith CG, Moldawer LL, Lowry SF: Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J Am Cell Surg 178:132–138, 1994
van Deuren M, van der Ven Jongekrijg J, Demacker PN, Bartelink AK, van Dalen R, Sauerweien RW, Gallati H, Vannice JL, van der Meer JW: Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infection. J Infect Dis 169:157–161, 1994
Akira S, Kishimoto T: IL6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev 127:25–50, 1992
Heinrich PC, Castell JV, Andus T: Interleukin 6 and the acute phase response. Biochem J 265:621–636, 1990
Clark SC: Interleukin 6. Multiple activities in regulation of the hematopoietic and immune systems. Ann NY Acad Sci 557:438–443, 1989
Helle M, Brakenhoff JPJ, de Groot ER, Aarden LA: Interleukin 6 is involved in interleukin 1 induced activities. Eur J Immunol 18:957–959, 1988
Ashcroft GS, Masterson GS: Interleukin-6 and wound healing. Br J Anaesth 73:426–432, 1994
Zhou D, Munster AM, Winchurch RA: Inhibitory effects of interleukin 6 on immunity. Possible implications in burn patients. Arch Surg 127:65–69, 1992
May LT, Viguet H, Kenney JS, Ida N, Allison AC, Sehgal PB: High levels of “complexed” interleukin-6 in human blood. J Biol Chem 267:19698–19704, 1992
May LT, Neta R, Moldawer LL, Kenney JS, Patel K, Seghal PB: Antibodies chaperone circulating IL-6. Paradoxical effects of anti-IL6 “neutralizing” antibodies in vivo. J Immunol 151:3225–3236, 1993
Matsushima K, Oppenheim JJ: Interleukin 8 and MCAF: Novel inflammatory cytokines inducible by IL1 and TNF. Cytokine 1:2–13, 1989
Baggiolini M, Walz A, Kunkel SL: Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 84:1045–1049, 1989
Van Zee KJ, DeForge LE, Fischer E, Marano MA, Kenney JS, Remick DG, Lowry SF, Oldawer LL: IL8 in septic shock, endotoxemia, and after IL1 administration. J Immunol 146:3478–3482, 1991
Martich GD, Danner RL, Ceska M, Suffredini AF: Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: The effect of anti-inflammatory agents. J Exp Med 173:1021, 1991
Danner RL, Suffredini AF, Dervort AL, Ceska M, Stetz PL, Zablotny JA, Patterson EA: Detection of interleukin 6 (IL-6) and interleukin 8 (IL-8) during septic shock in humans. Clin Res 38:352A, 1990
Garner WL, Rodriguez JL, Miller C, Smith DJ, Remick DG: Acute skin injury releases neutrophil chemoattractants. Surg Forum 42:617–618, 1991
de Waal Malefyt R, Abrams J, Bennett B, Figdor CC, de Vries JE: Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 174:1209–1220, 1991
Pradier O, Gerard C, Delvaux A, Lybin M, Abramowicz D, Capel P, Velu T, Goldman M: Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide. Eur J Immunol 23:2700–2703, 1993
Bogdan C, Vodovotz Y, Nathan C: Macrophage deactivation by interleukin-10. J Exp Med 174:1549–1555, 1991
Marchant A, Deviere J, Byl B, De Grotte D, Vincent J-L., Goldman M: Interleukin-10 production during septicemia. Lancet 1:707–708, 1994
Ayala A, Deol ZK, Lehman DL, Herdon CD, Chaundry IH: Polymicrobial sepsis but not low dose endotoxin infusion causes decreased splenocyte IL2/IFN gamma release while increasing IL-4/IL-10 production. J Surg Res 56:579–585, 1994
Abraham E, Chang Y-H: Haemorrhage-induced alterations in function and cytokine production of T cells and T cell subpopulations. Clin Exp Immunol 90:497–502, 1992
Ayala A, Lehman DL, Herdon CD, Chaudry IH: Interleukin (IL)-10 induced suppression of T-cell responses following hemorrhage (HEM) is mediated by eicosanoids. Intens Care Med 20:S59, 1994
Miller-Graziano CL, De AK, Kodys K: Altered IL10 levels in trauma patients' MØ and T lymphocytes. J Clin Immunol 15:93–104, 1995
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grzelak, I., Olszewski, W.L., Zaleska, M. et al. Blood cytokine levels rise even after minor surgical trauma. J Clin Immunol 16, 159–164 (1996). https://doi.org/10.1007/BF01540914
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01540914